LUCA Science is a pre-clinical biotechnology company that focuses on developing functional mitochondria as therapeutic agents to treat damaged tissues and organs. The company has pioneered a novel method known as Intact Mitochondrial Isolation Technology (iMIT), which allows for the isolation of proprietary, intact, and functional mitochondria. These mitochondria can be stored and delivered as biopharmaceutical agents, demonstrating the potential to improve bioenergetics in host cells within hours of incorporation. This innovative approach positions LUCA Science at the forefront of mitochondrial therapy, particularly in addressing inherited mitochondrial diseases.

In addition to its mitochondrial isolation technology, LUCA Science is actively building a mitochondrial engineering platform aimed at enhancing the quality and functionality of mitochondria from their source to the target delivery site. The company collaborates with leading academic and industry partners to explore meaningful clinical applications across various therapeutic areas. Their research has garnered attention, with publications in reputable journals and presentations at significant medical conferences, highlighting the potential of mitochondria transfer-based therapies in reducing morbidity and mortality associated with conditions like Leigh Syndrome.

Japan

We are a pre-clinical stage biotechnology company focused on developing functional mitochondria as therapeutic agents, an emerging platform to treat damaged tissues and organs.

LUCA Science

Company Details